Search

Madaiah Puttaraju

from Germantown, MD
Age ~63
Get Report
Also known as:
Madaiah Puttaragu, Madai Puttaraju, Madiah N Puttaraju, Puttaraju Madaiah, Sharon Peters, H Puttaraju, H U, Madia U
Phone and address:
12115 Stardrift Dr, Germantown, MD 20876
(301) 528-3865
Related to:
Ajay Vasanth Kumar, 29
Connected to:
Hemanth K Puttaswamy, 56Manohar B Puttaswamaiah, 41Christina L Puttbach, 58Jerry N Putteet, 89Trudy S Putteet, 75Eric R Putter, 60Sharon Putter, 55Steven Putter, 130Adam Putterman, 33Amy Putterman, 65

Madaiah Puttaraju Phones & Addresses

  • 12115 Stardrift Dr, Germantown, MD 20876 (301) 528-3865 (301) 916-4138
  • 416 Tall Oaks Dr, Durham, NC 27713 (919) 403-7217
  • 12115 Stardrift Dr, Germantown, MD 20876

Work

Company: Nci Sep 2012 Position: Special volunteer

Education

School / High School: Indian Institute of Science- Bangalore, Karnataka 1993 Specialities: Ph.D. in Biochemistry

Skills

Experienced scientist with >12 yrs R&...

Languages

Kannada • Tamil

Industries

Biotechnology

Resumes

Resumes

Madaiah Puttaraju Photo 1

Research Fellow

View page
Location:
Germantown, MD
Industry:
Biotechnology
Work:
Nci, Inc.
Research Fellow
Virxsys Sep 2007 - Mar 2012
Senior Scientist, Smart Development Group
Intronn Inc. Jun 1996 - Sep 2007
Scientist
Education:
Indian Institute of Science (Iisc) 1986 - 1992
Doctorates, Doctor of Philosophy, Biochemistry, Philosophy University of Mysore 1983 - 1985
Masters, Biochemistry
Skills:
3. Excellent Communication Skills and Presentation of Data at All Levels
6. Broad Experience In Writing and Implementing Animal Protocols
9. Design of Tox and Bio Distribution Studies
12. Experience In Handling and Maintenance of Various Cell Lines
16. Preparation and Analysis of Rna
17. Quantitative Real Time Pcr Techniques
21. In Depth Knowledge of Animal Models Used In Cardiovascular Field
22. Efficacy Studies In Normal and Knockout Mice
23. Use of Cell Factories For Aav and Lentivirus Production
24. Testing of Viral and Non Viral Delivery Systems In Vivo For Efficacy
Languages:
Kannada
Tamil
Madaiah Puttaraju Photo 2

Madaiah Puttaraju Germantown, MD

View page
Work:
NCI

Sep 2012 to 2000
Special Volunteer
SMaRT Development Group

2010 to 2012
Assistant Director
VIRxSYS Corp
Gaithersburg, MD
2007 to 2010
Senior Scientist III
Intronn Inc
Gaithersburg, MD
2005 to 2007
Senior Scientist II
Intronn LLC
Durham, NC
2000 to 2004
Senior Scientist
Intronn LLC
Durham, NC
1996 to 2000
Scientist
Duke University Medical Center
Durham, NC
1992 to 1996
Postdoctoral Research Associate
Education:
Indian Institute of Science
Bangalore, Karnataka
1993
Ph.D. in Biochemistry
University of Mysore
Mysore, Karnataka
1985
MSc in Biochemistry
University of Mysore
Mysore, Karnataka
1983
BSc in Biological Sciences
Skills:
Experienced scientist with >12 yrs R&D experience in both academic and biotech industry

Publications

Us Patents

Expression Of Apoai And Variants Thereof Using Spliceosome Mediated Rna Trans-Splicing

View page
US Patent:
7968334, Jun 28, 2011
Filed:
May 31, 2005
Appl. No.:
11/141447
Inventors:
Madaiah Puttaraju - Germantown MD, US
Edward Otto - Reston VA, US
Mariano A. Garcia-Blanco - Durham NC, US
Gerard J. McGarrity - Gaithersburg MD, US
Gary F. Temple - Washington Grove MD, US
Assignee:
VIRxSYS Corporation - Gaitherburg MD
International Classification:
C12N 5/00
C12N 15/12
C12N 15/63
C12N 15/87
US Classification:
435325, 435455, 435463
Abstract:
Methods and compositions for generating novel nucleic acid molecules through targeted spliceosome mediated RNA trans-splicing that result in expression of a apoAI protein, an apoAI variant, the preferred embodiment referred to herein as the apoAI Milano variant, a pre-pro-apoAI or an analogue of apoAI. The methods and compositions include pre-trans-splicing molecules (PTMs) designed to interact with a target precursor messenger RNA molecule (target pre-mRNA) and mediate a trans-splicing reaction resulting in the generation of a novel chimeric RNA molecule (chimeric RNA) capable of encoding apoAI, the apoAI Milano variant, or an analogue of apoAI. The expression of this apoAI protein results in protection against vascular disorders resulting from plaque build up, i. e. , atherosclerosis, strokes and heart attacks.

Correction Of Alpha-1-Antitrypsin Genetic Defects Using Spliceosome Mediated Rna Trans Splicing

View page
US Patent:
8053232, Nov 8, 2011
Filed:
Jan 21, 2005
Appl. No.:
11/040634
Inventors:
Madaiah Puttaraju - Germantown MD, US
Edward Otto - Reston VA, US
Mariano A. Garcia-Blanco - Durham NC, US
Gerard J. McGarrity - Gaithersburgh MD, US
Gary F. Temple - Washington Grove MD, US
Lloyd G. Mitchell - Bethesda MD, US
Colette Cote - Gaithersburgh MD, US
S. Gary Mansfield - Montgomery Village MD, US
Assignee:
VIRxSYS Corporation - Gaithersburg MD
International Classification:
C12N 5/00
C12N 15/12
C12N 15/63
C12N 15/86
US Classification:
435325, 4353201
Abstract:
The present invention provides methods and compositions for generating novel nucleic acid molecules through targeted spliceosomal mediated RNA trans-splicing. The compositions of the invention include pre-trans-splicing molecules (PTMs) designed to interact with a SERPINA1 target precursor messenger RNA molecule (target pre-mRNA) and mediate a trans-splicing reaction resulting in the generation of a novel chimeric RNA molecule (chimeric RNA). In particular, the PTMs of the present invention include those genetically engineered to interact with SERPINA1 target pre-mRNA so as to result in correction of SERPINA1 genetic defects responsible for AAT deficiency. The PTMs of the invention may also comprise sequences that are processed out of the PTM to yield duplex siRNA molecules directed specifically to mutant SERPIN A1 mRNAs. Such duplexed siRNAs are designed to reduce the accumulation of toxic AAT protein in liver cells. The methods and compositions of the present invention can be used in gene therapy for correction of SERPINA1 disorders such as AAT deficiency.

Methods And Compositions For Use In Spliceosome Mediated Rna Trans-Splicing

View page
US Patent:
20020115207, Aug 22, 2002
Filed:
Jan 8, 2001
Appl. No.:
09/756095
Inventors:
Lloyd Mitchell - Durham NC, US
Mariano Garcia-Blanco - Durham NC, US
Madaiah Puttaraju - Durham NC, US
S. Mansfield - Durham NC, US
International Classification:
C12P021/02
C12N005/06
C07H021/04
US Classification:
435/325000, 435/320100, 536/023100
Abstract:
The molecules and methods of the present invention provide a means for in vivo production of a trans-spliced molecule in a selected subset of cells. The pre-trans-splicing molecules of the invention are substrates for a trans-splicing reaction between the pre-trans-splicing molecules and a pre-mRNA which is uniquely expressed in the specific target cells. The in vivo trans-splicing reaction provides a novel mRNA which is functional as mRNA or encodes a protein to be expressed in the target cells. The expression product of the mRNA is a protein of therapeutic value to the cell or host organism a toxin which causes killing of the specific cells or a novel protein not normally present in such cells. The invention further provides PTMs that have been genetically engineered for the identification of exon/intron boundaries of pre-mRNA molecules using an exon tagging method. The PTMs of the invention can also be designed to result in the production of chimeric RNA encoding for peptide affinity purification tags which can be used to purify and identify proteins expressed in a specific cell type.

Methods And Compositions For Use In Spliceosome Mediated Rna Trans-Splicing

View page
US Patent:
20020193580, Dec 19, 2002
Filed:
Feb 12, 2002
Appl. No.:
10/076248
Inventors:
Lloyd Mitchell - Bethesda MD, US
Mariano Garcia-Blanco - Durham NC, US
Madaiah Puttaraju - Germantown MD, US
International Classification:
C07H021/02
C07H021/04
US Classification:
536/023100
Abstract:
The present invention provides methods and compositions for delivery of synthetic pre-trans-splicing molecules (synthetic PTMs) into a target cell. The compositions of the invention include synthetic pre-trans-splicing molecules (PTMs) with enhanced stability against chemical and enzymatic degradation. The synthetic PTMs are designed to interact with a natural target precursor messenger RNA molecule (target pre-mRNA) and mediate a trans-splicing reaction resulting in the generation of a novel chimeric RNA molecule (chimeric RNA).

Methods And Compositions For Use In Spliceosome Mediated Rna Trans-Splicing

View page
US Patent:
20030027250, Feb 6, 2003
Filed:
Aug 29, 2001
Appl. No.:
09/941492
Inventors:
Lloyd Mitchell - Durham NC, US
Mariano Garcia-Blanco - Durham NC, US
Carl Baker - Potomac MD, US
Madaiah Puttaraju - Durham NC, US
International Classification:
C12P021/02
C12N005/06
C12N015/86
US Classification:
435/069100, 435/325000, 435/456000
Abstract:
The molecules and methods of the present invention provide a means for in vivo production of a trans-spliced molecule in a selected subset of cells. The pre-trans-splicing molecules of the invention are substrates for a trans-splicing reaction between the pre-trans-splicing molecules and a pre-mRNA which is uniquely expressed in the specific target cells. The in vivo trans-splicing reaction provides a novel mRNA which is functional as mRNA or encodes a protein to be expressed in the target cells. The expression product of the mRNA is a protein of therapeutic value to the cell or host organism a toxin which causes killing of the specific cells or a novel protein not normally present in such cells. The invention further provides PTMs that have been genetically engineered for the identification of exon/intron boundaries of pre-mRNA molecules using an exon tagging method. The PTMs of the invention can also be designed to result in the production of chimeric RNA encoding for peptide affinity purification tags which can be used to purify and identify proteins expressed in a specific cell type.

Methods And Compositions For Use In Spliceosome Mediated Rna Trans-Splicing

View page
US Patent:
20030077754, Apr 24, 2003
Filed:
Jan 8, 2001
Appl. No.:
09/756096
Inventors:
Lloyd Mitchell - Durham NC, US
Mariano Garcia-Blanco - Durham NC, US
Madaiah Puttaraju - Durham NC, US
S. Mansfield - Durham NC, US
International Classification:
C12N009/00
C07H021/04
C12P021/04
C12N005/06
US Classification:
435/069700, 435/320100, 435/325000, 536/023200, 435/183000
Abstract:
The molecules and methods of the present invention provide a means for in vivo production of a trans-spliced molecule in a selected subset of cells. The pre-trans-splicing molecules of the invention are substrates for a trans-splicing reaction between the pre-trans-splicing molecules and a pre-mRNA which is uniquely expressed in the specific target cells. The in vivo trans-splicing reaction provides a novel mRNA which is functional as mRNA or encodes a protein to be expressed in the target cells. The expression product of the mRNA is a protein of therapeutic value to the cell or host organism a toxin which causes killing of the specific cells or a novel protein not normally present in such cells. The invention further provides PTMs that have been genetically engineered for the identification of exon/intron boundaries of pre-mRNA molecules using an exon tagging method. The PTMs of the invention can also be designed to result in the production of chimeric RNA encoding for peptide affinity purification tags which can be used to purify and identify proteins expressed in a specific cell type.

Methods And Compositions For Use In Spliceosome Mediated Rna Trans-Splicing

View page
US Patent:
20030153054, Aug 14, 2003
Filed:
Feb 12, 2002
Appl. No.:
10/075028
Inventors:
Lloyd Mitchell - Bethesda MD, US
Mariano Garcia-Blanco - Durham NC, US
Madaiah Puttaraju - Germantown MD, US
International Classification:
C12P019/34
C12N005/00
US Classification:
435/091200, 435/375000
Abstract:
The present invention provides methods and compositions for delivery of synthetic pre-trans-splicing molecules (synthetic PTMs) into a target cell. The compositions of the invention include synthetic pre-trans-splicing molecules (PTMs) with enhanced stability against chemical and enzymatic degradation. The synthetic PTMs are designed to interact with a natural target precursor messenger RNA molecule (target pre-mRNA) and mediate a trans-splicing reaction resulting in the generation of a novel chimeric RNA molecule (chimeric RNA).

Transgenic Animal Model For Spliceosome-Mediated Rna Trans-Splicing

View page
US Patent:
20030204861, Oct 30, 2003
Filed:
Apr 30, 2002
Appl. No.:
10/136723
Inventors:
Madaiah Puttaraju - Germantown MD, US
Lloyd Mitchell - Bethesda MD, US
John Engelhardt - Iowa City IA, US
Xiaoming Liu - Iowa City IA, US
International Classification:
A01K067/027
US Classification:
800/018000
Abstract:
The present invention relates to development of an animal model system for in vivo testing of spliceosome-mediated RNA trans-splicing reactions. The present invention provides transgenic animals, and methods for generating such animals, that have been genetically engineered to expresses a target precursor messenger RNA molecule (target pre-mRNA) that serves as a substrate for a trans-splicing reaction. Specifically, the transgenic animals contain at least one transgene capable of expressing a target pre-mRNA molecule. The invention provides methods, based on utilization of the transgenic animals, for assessing the specificity and efficiency of a pre-trans-splicing molecule (PTM) designed to interact with a target pre-mRNA and mediate a trans-splicing reaction resulting in the generation of a novel chimeric RNA molecule. The present invention further relates to the transgenic expression of PTM molecules in animals to determine gene function, i.e, functional genetics. The present invention is based on the successful generation of a transgenic animal expressing a target pre-mRNA and, moreover, the use of that animal to detect accurate in vivo trans-splicing reactions in the presence of a PTM.
Control profile
Madaiah Puttaraju from Germantown, MD, age ~63 Get Report